Wednesday, December 23, 2015 7:22:57 AM
Piper Jaffray analyst Joshua Schimmer views Celgene's settlement with Natco for the Revlimid Paragraph IV patent challenge as "creative and a positive." The news removes the overhang that allows the company to continue managing towards 25% annual earnings growth through the middle of the next decade, Schimmer tells investors in a research note. The agreement allows a limited generic launch in 2022, the analyst points out. Celgene remains one of his top biotech picks with an Overweight rating and $163 price target
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM